AS900672-Enriched 50 microgram (mcg) + AS900672-Enriched 100 mcg + AS900672-Enriched 150 mcg + Follitropin alfa 150 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Infertility
Conditions
Infertility
Trial Timeline
Jan 1, 2007 → Sep 1, 2008
NCT ID
NCT00505752About AS900672-Enriched 50 microgram (mcg) + AS900672-Enriched 100 mcg + AS900672-Enriched 150 mcg + Follitropin alfa 150 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG)
AS900672-Enriched 50 microgram (mcg) + AS900672-Enriched 100 mcg + AS900672-Enriched 150 mcg + Follitropin alfa 150 international unit (IU) + Recombinant human chorionic gonadotropin (r-hCG) is a phase 2 stage product being developed by Merck for Infertility. The current trial status is completed. This product is registered under clinical trial identifier NCT00505752. Target conditions include Infertility.
What happened to similar drugs?
10 of 20 similar drugs in Infertility were approved
Approved (10) Terminated (4) Active (10)
🔄GenSci094 + Placebo RecFSH / follitropin alfa + Biological: RecFSH / Follitropin alfa (Days 1 to 7) + Placebo GenSci094 + RecFSH / Follitropin alfa (Days 8 to hCG) + Ganirelix + hCG + ProgesteroneSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00505752 | Phase 2 | Completed |
Competing Products
20 competing products in Infertility